位置:首页 > 蛋白库 > GLOB_GLAL2
GLOB_GLAL2
ID   GLOB_GLAL2              Reviewed;         682 AA.
AC   S3DQQ3;
DT   20-JUN-2018, integrated into UniProtKB/Swiss-Prot.
DT   18-SEP-2013, sequence version 1.
DT   25-MAY-2022, entry version 20.
DE   RecName: Full=Pneumocandin biosynthesis cluster protein B {ECO:0000303|PubMed:25270390};
GN   Name=gloB {ECO:0000303|PubMed:25270390};
GN   Synonyms=GLHYP {ECO:0000303|PubMed:25879325}; ORFNames=GLAREA_10045;
OS   Glarea lozoyensis (strain ATCC 20868 / MF5171).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Leotiomycetes;
OC   Helotiales; Helotiaceae; Glarea.
OX   NCBI_TaxID=1116229;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], IDENTIFICATION, AND
RP   FUNCTION.
RC   STRAIN=ATCC 20868 / MF5171;
RX   PubMed=23688303; DOI=10.1186/1471-2164-14-339;
RA   Chen L., Yue Q., Zhang X., Xiang M., Wang C., Li S., Che Y.,
RA   Ortiz-Lopez F.J., Bills G.F., Liu X., An Z.;
RT   "Genomics-driven discovery of the pneumocandin biosynthetic gene cluster in
RT   the fungus Glarea lozoyensis.";
RL   BMC Genomics 14:339-339(2013).
RN   [2]
RP   FUNCTION.
RX   PubMed=25270390; DOI=10.1002/cbic.201402175;
RA   Houwaart S., Youssar L., Huettel W.;
RT   "Pneumocandin biosynthesis: involvement of a trans-selective proline
RT   hydroxylase.";
RL   ChemBioChem 15:2365-2369(2014).
RN   [3]
RP   FUNCTION, AND BIOTECHNOLOGY.
RX   PubMed=25879325; DOI=10.1021/acschembio.5b00013;
RA   Li Y., Chen L., Yue Q., Liu X., An Z., Bills G.F.;
RT   "Genetic manipulation of the pneumocandin biosynthetic pathway for
RT   generation of analogues and evaluation of their antifungal activity.";
RL   ACS Chem. Biol. 10:1702-1710(2015).
RN   [4]
RP   FUNCTION, AND BIOTECHNOLOGY.
RX   PubMed=25527531; DOI=10.1128/aem.03256-14;
RA   Chen L., Yue Q., Li Y., Niu X., Xiang M., Wang W., Bills G.F., Liu X.,
RA   An Z.;
RT   "Engineering of Glarea lozoyensis for exclusive production of the
RT   pneumocandin B0 precursor of the antifungal drug caspofungin acetate.";
RL   Appl. Environ. Microbiol. 81:1550-1558(2015).
RN   [5]
RP   FUNCTION, AND BIOTECHNOLOGY.
RX   PubMed=27494047; DOI=10.1021/acschembio.6b00604;
RA   Chen L., Li Y., Yue Q., Loksztejn A., Yokoyama K., Felix E.A., Liu X.,
RA   Zhang N., An Z., Bills G.F.;
RT   "Engineering of new pneumocandin side-chain analogues from Glarea
RT   lozoyensis by mutasynthesis and evaluation of their antifungal activity.";
RL   ACS Chem. Biol. 11:2724-2733(2016).
RN   [6]
RP   FUNCTION.
RX   PubMed=29352089; DOI=10.1128/aem.02370-17;
RA   Mattay J., Houwaart S., Huettel W.;
RT   "Cryptic production of trans-3-hydroxyproline in echinocandin B
RT   biosynthesis.";
RL   Appl. Environ. Microbiol. 0:0-0(2018).
RN   [7]
RP   REVIEW.
RX   PubMed=27705900; DOI=10.1515/znc-2016-0156;
RA   Huettel W.;
RT   "Structural diversity in echinocandin biosynthesis: the impact of oxidation
RT   steps and approaches toward an evolutionary explanation.";
RL   Z. Naturforsch. C 72:1-20(2017).
CC   -!- FUNCTION: Part of the gene cluster that mediates the biosynthesis of
CC       pneumocandins, lipohexapeptides of the echinocandin family that prevent
CC       fungal cell wall formation by non-competitive inhibition of beta-1,3-
CC       glucan synthase (PubMed:27705900). The 10,12-dimethylmyristoyl side
CC       chain is synthesized by the reducing polyketide synthase gloL/GLPKS4
CC       (PubMed:27494047). The thioesterase gloN/GLHYD exclusively interacts
CC       with gloL/GLPKS4 to maintain turnover of the polyketide side chain
CC       (PubMed:27494047). The 10R,12S-dimethylmyristic acid is then
CC       transferred to the first thiolation domain of the nonribosomal peptide
CC       synthetase gloA/GLNRPS4 by the acyl-AMP ligase gloD/GLligase, followed
CC       by its acylation to L-ornithine to trigger elongation of the cyclic
CC       hexapeptide (PubMed:27494047). L-ornithine, 4R-hydroxyl-L-proline
CC       (generated from L-proline by the dioxygenase gloF/GLOXY2), 3S-hydroxyl-
CC       L-homotyrosine (generated by gloG/GLHtyB, gloH/GLHtyA, gloI/GLHtyC,
CC       gloJ/GLHtyD and hydroxylated at C-3 by the dioxygenase gloM/GLOXY1),
CC       3R-hydroxyl-L-glutamine (generated from L-glutamine probably by the
CC       dioxygenase gloE/GLOXY3) and 3S-hydroxyl-L-proline (generated from L-
CC       proline by the dioxygenase gloF/GLOXY2 to yield pneumocandin B0), or
CC       3S-hydroxyl-4S-methyl-L-proline (generated from L-leucine by the
CC       dioxygenase gloC/GLOXY4 to yield pneumocandin A0) are sequentially
CC       added to the growing chain (PubMed:25270390, PubMed:25879325,
CC       PubMed:25527531). The last C domain of gloA/GLNRPS4 is proposed to be
CC       responsible for cyclization by condensation to form the peptide bond
CC       between L-ornithine and 3S-hydroxyl-4S-methyl-L-proline (for
CC       pneumocandin A0) or 3S-hydroxyl-L-proline (for pneumocandin B0).
CC       Finally, the subsequent C-4 hydroxylation of 3S-hydroxyl-L-homotyrosine
CC       and L-ornithine dihydroxylation at C-4 and C-5 are performed by the
CC       cytochrome P450 monooxygenases gloP/GLP450-1 and gloO/GLP450-2,
CC       respectively (PubMed:25879325). {ECO:0000269|PubMed:25270390,
CC       ECO:0000269|PubMed:25527531, ECO:0000269|PubMed:25879325,
CC       ECO:0000269|PubMed:27494047, ECO:0000269|PubMed:29352089,
CC       ECO:0000303|PubMed:27705900}.
CC   -!- BIOTECHNOLOGY: Pneumocandin B0 is the starting molecule for the first
CC       semisynthetic echinocandin antifungal drug, caspofungin acetate
CC       (PubMed:25527531). Pneumocandin B0 is a minor fermentation product, and
CC       its industrial production was achieved by a combination of extensive
CC       mutation and medium optimization (PubMed:25527531). Inactivation of
CC       three of gloP/GLP450-1, gloO/GLP450-2, and gloM/GLOXY1 generates 13
CC       different pneumocandin analogs that lack one, two, three, or four
CC       hydroxyl groups on 4R,5R-dihydroxy-ornithine and 3S,4S-dihydroxy-
CC       homotyrosine of the parent hexapeptide (PubMed:25879325). All of these
CC       cyclic lipopeptides show potent antifungal activities, and two new
CC       metabolites pneumocandins F and G are more potent in vitro against
CC       Candida species and Aspergillus fumigatus than the principal
CC       fermentation products, pneumocandins A0 and B0 (PubMed:25879325).
CC       Moreover, feeding alternative side chain precursors yields acrophiarin
CC       and 4 additional pneumocandin congeners with straight C14, C15, and C16
CC       side chains. One of those compounds, pneumocandin I, has elevated
CC       antifungal activity and similar hemolytic activity compared to
CC       pneumocandin B0, the starting molecule for caspofungin, demonstrating
CC       the potential for using gloD/GLligase for future engineering of new
CC       echinocandin analogs (PubMed:27494047). {ECO:0000269|PubMed:25527531,
CC       ECO:0000269|PubMed:25879325, ECO:0000269|PubMed:27494047}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KE145356; EPE34351.1; -; Genomic_DNA.
DR   RefSeq; XP_008078286.1; XM_008080095.1.
DR   AlphaFoldDB; S3DQQ3; -.
DR   EnsemblFungi; EPE34351; EPE34351; GLAREA_10045.
DR   GeneID; 19469092; -.
DR   KEGG; glz:GLAREA_10045; -.
DR   eggNOG; ENOG502T008; Eukaryota.
DR   HOGENOM; CLU_403347_0_0_1; -.
DR   OrthoDB; 1596001at2759; -.
DR   Proteomes; UP000016922; Unassembled WGS sequence.
PE   1: Evidence at protein level;
KW   Reference proteome.
FT   CHAIN           1..682
FT                   /note="Pneumocandin biosynthesis cluster protein B"
FT                   /id="PRO_0000444487"
FT   REGION          63..86
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          107..129
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          251..358
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        63..80
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        251..293
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        311..335
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   682 AA;  76217 MW;  4E5C740FA6A8BA37 CRC64;
     MDLFQSPGGD LIQDEDSVEV IEMLCIDFRD RLLVALSTTC QSDFREAKKV VEERLRDILE
     TASSLSSTEV TSSPNASPLY NTDAPEDVVP TVGLDVGLDE PMADYSQNTP SITGGTASAE
     YQNSGDTNQM TLEDPACVDM FAAESQNTGH IPDSCLRDWS FEGVSMKSPS LFDWSSRNSN
     FPLTQEHENQ FAEFLTLFEG EPNFDNWLST MTWSSLESHS SPINGHSAGA TPQLDQMHTV
     SNSRVARSVV SESTVTNTGS ANSLNSGLLA NTPSSSHSSV FERACSSVQE PTPEPTPVRG
     LQRKLRKQGP RQTTEATPCD QQIGPRASRA TSQLPERRSM KMVRKEARDT PLTTSPANST
     QINIEANTIP SDLSVEYAFG CFSDAKEVFE TFYKRLSDDR KHLSSLLMRL FYAVGSPDAL
     RQLRDALDLS RKNSMIASYH DSNDLAATVS VLDQLDATTT LSHILRRYHL VRLLDHRSKL
     ESNHKAAKLA VKGTKRRLKY DCERIELMRR GENADCDANT RSAKERLKYR SKTRALTDLM
     QTLYPDLSPD SEGITTAGGC EYTRKLTKLR NRLACARNWY QFEETFPGAI LALIPCATGD
     LSISIDHVEK LPSDVLKIFL DYLKERRGVF LSKMSRILSK DLYDVLMRRN VTKRYKLEQT
     NENSLTDGLH DDDRLLELCE TV
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024